Aptevo Therapeutics Stock Soars 16.88% on Clinical Trial Success

On April 23, 2025, Aptevo Therapeutics' stock surged by 16.88% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Aptevo Therapeutics has seen a notable increase in its stock price, driven by promising results from its clinical trials. The company reported a 90% remission rate in its RAINIER Phase 1b/2 trial for acute myeloid leukemia (AML), which has boosted investor confidence and contributed to the stock's recent surge.

Additionally, Aptevo Therapeutics announced a $2 million stock offering, which has been met with mixed reactions from the market. While some investors view this as a positive move to raise capital for further research and development, others are cautious about the potential dilution of existing shares.